XI3.F BIOCELTIX S.A. ZY -10
- Market cap
- EUR 113M
- P/E
- -
- P/B
- 7.95x
- ROE
- -34.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is XI3.F undervalued?
Graham numberThe Graham number of BIOCELTIX S.A. ZY -10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOCELTIX S.A. ZY -10 fundamental analysis
No fundamental analysis for BIOCELTIX S.A. ZY -10 yet.
BIOCELTIX S.A. ZY -10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project…
Full company profileBIOCELTIX S.A. ZY -10 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIOCELTIX S.A. ZY -10 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -854K | -700K | -1.04M | -1.43M | -2.04M | -3.38M |
| Operating Income | -4.40M | -8.95M | -14.0M | -14.7M | -15.2M | -21.6M |
| EBITDA | - | -8.49M | -13.2M | -13.8M | -14.3M | -20.7M |
| Net Income | -4.40M | -8.92M | -13.7M | -14.5M | -15.2M | -21.5M |
| EPS | -1.34 | -2.60 | -3.31 | -2.95 | -2.74 | -3.89 |
| Balance Sheet | ||||||
| Total Assets | 8.20M | 7.65M | 12.7M | 41.9M | 75.6M | 65.7M |
| Total Liabilities | 2.20M | 2.50M | 2.27M | 3.44M | 2.36M | 3.20M |
| Shareholders' Equity | 6.00M | 5.15M | 10.5M | 38.4M | 73.3M | 62.5M |
| Cash & Short-term Investments | 6.05M | 4.12M | 9.31M | 33.6M | 68.4M | 56.8M |
| Cash Flow | ||||||
| Operating Cash Flow | -4.02M | -7.87M | -14.7M | -17.6M | -11.9M | -17.4M |
| Capital Expenditure | 5.98K | 352K | 458K | 243K | 1.97M | 5.31M |
| Free Cash Flow | -4.02M | -8.23M | -15.2M | -17.8M | -13.9M | -22.7M |
| Ratios | ||||||
| ROE | -73.3% | -173.2% | -130.8% | -37.8% | -20.7% | -34.4% |
| ROA | -53.7% | -116.6% | -107.5% | -34.7% | -20.0% | -32.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
BIOCELTIX S.A. ZY -10 dividends
BIOCELTIX S.A. ZY -10 has not paid dividends in the last 5 fiscal years.
Who owns BIOCELTIX S.A. ZY -10
- Insiders 15.12%
- Institutions 28.83%
- Public & others 56.05%
- Shares outstanding 5.53M
- Free float 4.44M
BIOCELTIX S.A. ZY -10 company profile
- Company name
- BIOCELTIX S.A. ZY -10
- Ticker
- XI3.F
- ISIN
- PLBCLTX00019
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Fiscal year end
- December
- Address
- bud. III, Wroclaw, Poland, 51-317
- Phone
- 48 534 37 38 08
- Website
- bioceltix.com
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
BIOCELTIX S.A. ZY -10 management
10- Mr. Lukasz BzdzionCEO & President of the Management Board
- Dr. Pawel Wielgus Eng., Ph.D.Member of the Management Board
- Andrij WlachChief Financial Officer
- Mr. Grzegorz OstropolskiChief Operating Officer
- Mr. Lahoud ToumaDirector of Technology
- Mr. Jakub WacekLegal Counsel & General Counsel
- Dr. Patryk Reniewicz Ph.D.Head of R&D and Leader of the In Vitro Diagnostics Development Team
- Ms. Agnieszka KielczykowskaHead of Procurement & Supply
- Ms. Anna Olko-ChudyHead of the Management Office & Tissue Coordinator
- Ms. Katarzyna WroblewskaHead of Quality Assurance